A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
← catalyst calendarNCT07016750 · readout ≤ 134 d
Sponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
16estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-20 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dystrophic Epidermolysis Bullosa
- DEB - Dystrophic Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
- Dominant Dystrophic Epidermolysis Bullosa
Interventions
- Biological: KB803
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of KB803.
measured 24 weeks
To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms.
measured 24 weeks
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed